Product Description
STSA-1005 is being developed by Staidson (Beijing) Biopharmaceuticals for the treatment of severe COVID-19 indications. (Sourced from: https://www.staidsonbio.com/stsa-1005-injection-gains-approval-from-the-u-s-fda-to-conduct-clinical-trials/)
Mechanisms of Action: GM-CSF Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Staidson Biopharma
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05559125 |
STSA-1002/1005-01 | P1 |
Terminated |
Healthy Volunteers |
2024-03-26 |
12% |
2024-05-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05085197 |
STSA-1005-01 | P1 |
Completed |
Healthy Volunteers |
2022-04-05 |
12% |
2022-04-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|